Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics May 22 | 2026May CHMP Meeting Highlights; Lilly ATTAIN-1 and -2 Sub-analyses; Updated Beta Bionics Patch Pump Timeline; Novo Establishes UAE Distribution HubPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics May 21 | 2026Lilly Delivers Best-in-class Weight Loss with New Reta Data; Bayer’s Kerendia Receives Priority ReviewPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 19 | 2026New Regeneron Obesity Asset; China-Based Oral GLP-1RA Touts Better Results than Orforglipron; Pfizer’s VESPER-6 PostedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, Topics May 18 | 2026Another FDA Official Fired; AZ’s Baxdrostat Approved for HTN; Dexcom Flex to Launch in Germany; May CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 15 | 2026Generic Sema Now in Canada; Roche Posts Petrelintide + Enicepatide Study; Lilly Posts Ph2 Macupatide + Eloralintide Combo Study in ObesityPurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics May 15 | 2026Dexcom 2026 Investor Day; “Self-Adapting” G8 CGM to Launch Late-2027Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics May 14 | 2026ProRx FDA Warning Letter; Lilly Partners with UNICEFPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics May 13 | 2026Makary Resigns; Novo OASIS 4 Data; Altimmune Q1 ’26 Earnings; Lilly SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN Full Data; Insulet Initiates O6 vs. O5 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics May 12 | 2026STEP UP Wegovy HD Data; New Novo Obesity + T1DM Study; Fractyl Q1 ’26 Earnings and CTA Authorization of RJVA-001; Roche 2026 Diagnostics DayPurchase Blast
$599
Posted in: Other, Topics May 11 | 2026Cytokinetics Shares Aficamten Data; FDA Launches Pilot One-Day Inspectional AssessmentsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics May 08 | 2026Arrowhead, Structure, Senseonics, and Tandem Q1 ’26 Earnings; New Pfizer Obesity Combination StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 07 | 2026Sanofi to Pull Tzield Application from CNPV Program; Zealand Q1 ’26 Earnings; GSK Targets ALK7; Lilly Expands US Manufacturing Investment; Roche Acquires PathAIPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics May 06 | 2026Madrigal and Insulet Q1 ’26 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics May 06 | 2026Wegovy Pill Shines As Novo Raises FY 2026 guidance; Q1 ’26 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 05 | 2026Pfizer and Vertex Q1 ’26 Earnings; Madrigal Partners for siRNA MASH Asset; Novo Evaluates New Dose of Cagrisema; Cytokinetics Shares Topline ACACIA-HCM ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics May 04 | 2026Sirius Posts New Obesity Study; Amgen Expands US Manufacturing Investment; Insulet Initiates T2DM FCL StudyPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, Topics May 01 | 2026Amgen and Dexcom Q1 ’26 Earnings; Zealand to Elect Camilla Sylvest to Board; Esperion Gets Acquired; Senseonics Announces $80M Public Offering; Ozempic Pill Launches in USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 30 | 2026Lilly, Viking, and Merck Q1 ’26 Earnings; FDA Semaglutide and Tirzepatide Compounding ExclusionsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Apr 29 | 2026AZ, AbbVie, Regeneron, Ionis, and GSK Q1 ’26 Earnings; Zealand and Roche to Advance Petrelintide to Ph3Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 28 | 2026Topline SYNCHRONIZE-1 Data; Rocket Sells PRV; Novartis Q1 ’26 Earnings; Biomea COVALENT-112 DataPurchase Blast